Background: Follicle-stimulating hormone receptor (FSHR) has been shown to be expressed in ovarian cancer. Methods: Here we have summarized the potential therapeutic and diagnostic implication of FSHR in the ovarian cancers based on a review of the literature. Results: Current research indicates that FSHR comprises several variants: FSHR-1, FSHR-2, FSHR-3 and FSHR-4. Only FSHR-1 and FSHR-3 have biological roles. Although the level of FSHR differs in ovarian cancer tissues, few quantitative correlations have so far been reported on the expression levels of FSHR and carcinogenesis and progression of cancers. Conclusion: A comprehensive understanding of the role of FSHR in the ovarian cancers may help the search for novel therapeutic and diagnostic regimens and improve the management of cancer patients.

Journal Section:
Review Article
Keywords:
Follicle-stimulating hormone, FSH receptor, Overexpression, Carcinogenesis, Ovarian cancers
1.
Szkudlinski MW: New frontier in glycoprotein hormones and their receptors Structure function. Front Endocrinol (Lausanne). 2015;6:155.
[PubMed]
https://doi.org/10.3389/fendo.2015.00155
2.
Navalakhe RM, Jagtap DD, Nayak SU, et al.: Effect of FSH receptor-binding inhibitor-8 on FSH-mediated granulosa cell signaling and proliferation. Chem Biol Drug Des 2013;82:178-188.
[PubMed]
https://doi.org/10.1111/cbdd.12149
3.
Wei S, Shen X, Gong Z, et al.: FSHR and LHR expression and signaling as well as maturation and apoptosis of cumulus oocyte complexes following treatment with FSH receptor binding inhibitor in sheep. Cell Physiol Biochem 2017;43:660-669.
[PubMed]
https://doi.org/10.1159/000480650
4.
Xiao X, Zi X, Niu H: Effect of addition of FSH, LH and proteasome inhibitor MG132 to in vitro maturation medium on the developmental competence of yak (Bos grunniens) oocytes. Reprod Biol Endocrinol 2014;12:30-31.
[PubMed]
https://doi.org/10.1186/1477-7827-12-30
5.
Bonci EA, Irimie A, Buiga R, et al.: Follicle-stimulating hormone receptors: A new immunohistochemical marker in cancers? J BUON 2017;22:1352-1359.
[PubMed]
6.
Crepin R, Veggiani G, Djender S, et al.: Whole-cell biopanning with a synthetic phage display library of nanobodies enabled the recovery of follicle-stimulating hormone receptor inhibitors. Biochem Biophys Res Commun 2017;493:1567-1572.
[PubMed]
https://doi.org/10.1016/j.bbrc.2017.10.036
7.
Kleinau G, Neumann S, Grüters A, et al.: Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocrinol Rev 2013;34:691-724.
[PubMed]
https://doi.org/10.1210/er.2012-1072
8.
Troppmann B, Kleinau G, Krause G, Gromoll J: Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum Reprod Update 2013;19:583-602.
[PubMed]
https://doi.org/10.1093/humupd/dmt023
9.
Banerjee AA, Dupakuntla M, Pathak BR, Mahale SD: FSH receptor specific residues L501 and I505 in extracellular loop 2 are essential for its function. J Mol Endocrinol 2015;54:193-204.
[PubMed]
https://doi.org/10.1530/JME-14-0275
10.
Papadimitriou K, Kountourakis P, Kottorou AE, et al.: Follicle stimulating hormone receptor (FSHR): A promising tool in oncology? Mol Diagn Ther 2016; 20:523-530.
[PubMed]
https://doi.org/10.1007/s40291-016-0218-z
11.
Ghezelayagh Z, Totonchi M, Zarei-Moradi S, et al.: The impact of genetic variation and gene expression level of the follicle-stimulating hormone receptor on ovarian reserve. Cell J 2018;19:620-626.
[PubMed]
https://doi.org/10.22074/cellj.2018.4183
12.
Simoni M, Nieschlag E, Gromoll J: Isoforms and single nucleotide polymorphisms of the FSH receptor gene: Implications for human reproduction. Hum Reprod Update 2002;8:413-421.
[PubMed]
https://doi.org/10.1093/humupd/8.5.413
13.
Achrekar SK, Modi DN, Meherji PK, et al.: Follicle stimulating hormone receptor gene variants in women with primary and secondary amenorrhea. J Assist Reprod Genet 2010;27:317-326.
[PubMed]
https://doi.org/10.1007/s10815-010-9404-9
14.
Sullivan RR, Faris BR, Eborn D, et al.: Follicular expression of follicle stimulating hormone receptor variants in the ewe. Reprod Biol Endocrinol 2013;11:113.
[PubMed]
https://doi.org/10.1186/1477-7827-11-113
15.
Gharesifard B, Ghasemi Z, Shakeri S, et al.: The frequency of follicle stimulating hormone receptor gene polymorphisms in Iranian infertile men with azoospermia. Iran J Reprod Med. 2015;13:673-678.
[PubMed]
16.
Robinson LJ, Tourkova I, Wang Y, et al.: FSH-receptor isoforms and FSH-dependent gene transcription in human monocytes and osteoclasts. Biochem Biophys Res Commun 2010;394:12-17.
[PubMed]
https://doi.org/10.1016/j.bbrc.2010.02.112
17.
Zhou J, Huang Y, Li L, et al.: Identification of two novel, alternatively spliced mRNA transcripts of the human follicle stimulating hormone receptor. Mol Reprod Dev 2013;80:916-923.
[PubMed]
https://doi.org/10.1002/mrd.22227
18.
Ulloa-Aguirre A, Uribe A, Zariñán T, et al.: Role of the intracellular domains of the human FSH receptor in G (alpha) protein coupling and receptor expression. Mol Cell Endocrinol 2007;260-262:153-162.
[PubMed]
https://doi.org/10.1016/j.mce.2005.11.050
19.
Hunzicker-Dunn M, Maizels ET: FSH signaling pathways in immature granulosa cells that regulate target gene expression: Branching out from protein kinase A. Cell Signal 2006;18:1351-1359.
[PubMed]
https://doi.org/10.1016/j.cellsig.2006.02.011
20.
Bhartiya D, Singh J: FSH-FSHR3-stem cells in ovary surface epithelium: Basis for adult ovarian biology, failure, aging, and cancer. Reproduction 2015;149: R35-48.
[PubMed]
https://doi.org/10.1530/REP-14-0220
21.
Ulloa-Aguirre A, Zariñán T: The follitropin receptor: Matching structure and function. Mol Pharmcol. 2016;90:596-608.
[PubMed]
https://doi.org/10.1124/mol.116.104398
22.
Radu A, Pichon C, Camparo P: Expression of follicle stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621-1630.
[PubMed]
https://doi.org/10.1056/NEJMoa1001283
23.
Renner M, Goeppert B, Siraj MA, et al.: Follicle-stimulating hormone receptor expression in soft tissue sarcomas. Histopathology 2013;63:29-35.
[PubMed]
https://doi.org/10.1111/his.12135
24.
Onisim A, Iancu M, Vlad C, et al.: Expression of Nestin and CD133 in serous ovarian carcinoma. J BUON 2016;21:1168-1175.
[PubMed]
25.
Heublein S, Vrekoussis T, Mayr D: Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). J Ovarian Res 2013;6:6.
[PubMed]
https://doi.org/10.1186/1757-2215-6-6
26.
Zhang Z, Jia L, Feng Y, Zheng W: Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett 2009;278:56-64.
[PubMed]
https://doi.org/10.1016/j.canlet.2008.12.024
27.
Lenhard M, Lennerová T, Ditsch N, et al.: Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology 2011;58:990-994.
[PubMed]
https://doi.org/10.1111/j.1365-2559.2011.03848.x
28.
Heubner M, Riemann K, Otterbach F: The haplotype of two FSHR polymorphisms in ovarian cancer-a potential role of ethnology in risk modification. Gynecol Oncol 2009;112:486-489.
[PubMed]
https://doi.org/10.1016/j.ygyno.2008.12.011
29.
Perales-Puchalt A, Svoronos N, Rutkowski MR, et al.: Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 2017;23:441-453.
[PubMed]
https://doi.org/10.1158/1078-0432.CCR-16-0492
30.
Malivindi R, Rose DD, Santoro M, et al.: Follicle-stimulating hormone receptor (FSHR) a promising novel target for cancer diagnosis in seminoma and embryonal carcinoma. Ital J Anat Embryol 2017;122(Suppl): 128.
31.
Planeix F, Siraj MA, Bidard FC, et al.: Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery. J Exp Clin Cancer Res 2015;34:12.
[PubMed]
https://doi.org/10.1186/s13046-015-0128-7
32.
Stilley JA, Christensen DE, Dahlem KB, et al.: FSH receptor (FSHR) expression in human extragonadal reproductive tissues and the developing placenta, and the impact of its deletion of pregnancy in mice. Biol Reprod 2014;91:74.
[PubMed]
https://doi.org/10.1095/biolreprod.114.118562
33.
Siraj MA, Desestret V, Antoine M, et al.: Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC Cancer 2013;13:246.
[PubMed]
https://doi.org/10.1186/1471-2407-13-246
34.
Cannon JG, Kraj B, Sloan, G: Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine 2011;53:141-144.
[PubMed]
https://doi.org/10.1016/j.cyto.2010.11.011
35.
Song Y, Wang ES, Xing LL, et al.: Follicle-stimulating hormone induces postmenopausal dyslipidemia through inhibiting hepatic cholesterol metabolism. J Clin Endocrinol Metab 2016;101:254-263.
[PubMed]
https://doi.org/10.1210/jc.2015-2724
36.
Ulloa-Aguirre A, Zariñán T, Dias JA, Conn PM: Mutations in G protein coupled receptors that impact receptor trafficking and reproductive function. Mol Cell Endocrinol 2014;382:411-423.
[PubMed]
https://doi.org/10.1016/j.mce.2013.06.024
37.
Robin B, Planeix F, Sastre-Garau X, et al.: Follicle-stimulating hormone receptor expression in endometriotic lesions and the associated vasculature: An immunohistochemical study. Sci Reprod Sci 2016;23:885-891.
[PubMed]
https://doi.org/10.1177/1933719115623647
38.
Pawlikowski M, Jaranowska M, Pisarek H, et al.: Ectopic expression of follicle-stimulating hormone receptors in thyroid tumors. Arch Med Sci 2015;11:1314-1317.
[PubMed]
https://doi.org/10.5114/aoms.2015.56357
39.
Zidi S, Stayoussef M, Alsaleh BL, et al.: Effect of follicle stimulating hormone receptor gene polymorphisms in cervical cancer risk. Pathol Oncol Res 2017;23:565-572.
[PubMed]
https://doi.org/10.1007/s12253-016-0152-8
40.
Ghiringhelli F, Isambert N, Ladoire S: Degarelix as a new antiangiogenic agent for metastatic colon cancer? World J Gastroenterol 2013;19:769-772.
[PubMed]
https://doi.org/10.3748/wjg.v19.i5.769
41.
Urbanska K, Stashwick C, Poussin M, Powell DJ Jr: Follicle stimulating hormone receptor as a target in the redirected T-cell therapy for cancer. Cancer Immunol Res 2015;3:1130-1137.
[PubMed]
https://doi.org/10.1158/2326-6066.CIR-15-0047
© 2018 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.